Connect
MJA
MJA

Rosiglitazone and cardiovascular disease revisited

Timothy M E Davis and Johannes B Prins
Med J Aust 2010; 193 (3): 134-135.
Published online: 2 August 2010

Evidence concerning the safety of rosiglitazone continues to evolve

In February 2010, the United States Senate Committee on Finance released a report on the safety of rosiglitazone.1 The report concluded that there were possible cardiac risks associated with rosiglitazone and that the manufacturer, GlaxoSmithKline (GSK), was aware of this well before it became public. The authors further stated that, rather than warn patients and regulatory authorities promptly, GSK executives chose to intimidate independent physicians who publicised the possible risks, minimise the impact of adverse findings, and downplay the possibly beneficial cardiovascular effects of the other available drug in the class, pioglitazone.1

  • Timothy M E Davis1
  • Johannes B Prins2

  • 1 Department of Medicine, University of Western Australia, Fremantle, WA.
  • 2 Mater Medical Research Institute and University of Queensland, Brisbane, QLD.

Correspondence: tdavis@cyllene.uwa.edu.au

Competing interests:

Timothy Davis has served on advisory boards for Eli Lilly (which markets pioglitazone in Australia) and GSK, has had the costs of attendance at national and international scientific meetings covered by both companies, and has received lecture fees from GSK. Johannes Prins has served on advisory boards for GSK, and has had the costs of attendance at national and international scientific meetings covered and received lecture fees from both GSK and Eli Lilly.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.